Palisade Bio (PALI) Short-Term Debt issuances (2020 - 2021)
Palisade Bio (PALI) reported Short-Term Debt issuances of $1.2 million for Q1 2021, up 1150.0% on a QoQ basis from $100000.0 in Q3 2020.
Palisade Bio (PALI) has 2 years of Short-Term Debt issuances data on file, last reported at $1.2 million in Q1 2021.
- Quarterly Short-Term Debt issuances changed N/A year-over-year to $1.2 million in Q1 2021, while the trailing twelve-month figure through Dec 2021 was $1.2 million (changed N/A YoY) and the FY2021 annual result came in at $1.2 million, up 229.82% from the prior year.
- Short-Term Debt issuances grew to $1.2 million in Q1 2021 per PALI's latest filing, from $100000.0 in the prior quarter.
- Across five years, Short-Term Debt issuances topped out at $1.2 million in Q1 2021 and bottomed at $100000.0 in Q3 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -33,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 1.25 Mn |
| Mar 31, 2021 | 1.25 Mn |
| Sep 30, 2020 | 100,000.00 |
| Sep 30, 2020 | 100,000.00 |